GlassScriptPhysician profile
Satinder Dhillon
NPI 1477628147
$3,753.94
in general payments reported to CMS, 2019-2025
45 companies · $15.73 in 2025
The $15.73 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,940 · 2020: $736 · 2023: $25.21 · 2024: $36.86 · 2025: $15.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $52.59 · Education: $25.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $52.59 |
| Education | $25.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $264.62 | 2019-2025 | Opdivo |
| Pfizer INC. | $256.47 | 2019-2020 | |
| Genentech USA, INC. | $242.37 | 2019-2020 | |
| Janssen Biotech, INC. | $231.38 | 2019 | |
| Eisai INC. | $217.47 | 2019-2020 | |
| Astellas Pharma US INC | $211.92 | 2019-2020 | |
| Octapharma USA, INC. | $196.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $179.31 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $165.54 | 2019-2020 | |
| Seagen INC. | $152.24 | 2019-2020 | |
| Exelixis INC. | $135.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $121.04 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $100.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $97.84 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satinder Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.